Evidence map›Paper›PMID 37601886›Full record

ArticleEJHaem2023

Early diagnosis of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, with modified diagnostic criteria including refractory thrombocytopenia.

Hiroya Ichikawa, Kimikazu Yakushijin, Yoshiharu Miyata, Hirofumi Kanehira, Miki Joyce, Yuri Hirakawa, Sakuya Matsumoto, Shigeki Nagao, Rina Sakai, Keiji Kurata and 8 more

Open access · diamondAbstract read
In one paragraph

Article in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Hiroya IchikawaDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Kimikazu YakushijinDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.ORCID https://orcid.org/0000-0003-2511-7857
Yoshiharu MiyataBioResource Center Kobe University Hospital Kobe Japan.
Hirofumi KanehiraDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Miki JoyceDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Yuri HirakawaDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Sakuya MatsumotoDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Shigeki NagaoDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Rina SakaiDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Keiji KurataDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Akihito KitaoDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Yasuyuki SaitoDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Shinichiro KawamotoTransfusion Medicine and Cell Therapy Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Katsuya YamamotoDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Mitsuhiro ItoDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Tohru MurayamaDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Hiroshi MatsuokaBioResource Center Kobe University Hospital Kobe Japan.ORCID https://orcid.org/0000-0003-4443-4372
Hironobu MinamiDivision of Medical Oncology/Hematology Department of Medicine Kobe University Hospital and Graduate School of Medicine Kobe Japan.
Kobe University Hospital · JPHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sinusoidal obstruction syndrome (SOS) is a fatal complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis for SOS can improve clinical outcomes significantly. Here, we performed a retrospective study to investigate the Cairo diagnostic criteria, in which SOS was defined as the development of two or more in seven events, including transfusion-refractory thrombocytopenia. Among 154 cases of allogeneic HSCT, 10 cases of SOS using the European Society for Blood and Marrow Transplantation criteria (EBMT16) as the reference standard were identified. The original Cairo criteria could diagnose SOS 5 days earlier than any other established criteria, with some false-positive results (sensitivity = 100.0%; specificity = 72.2%). When the cutoff was set to three events for the Cairo criteria, the diagnosis of SOS could be made 3 days earlier than that using the EBMT16 criteria, with comparable precision (specificity = 86.1%). The accuracy of the Cairo criteria improved further when the cutoff point was set to four (specificity = 93.8%). The fulfillment of the Cairo criteria was associated with high mortality. Based on our results, the Cairo criteria were also considered clinically useful, especially at three or four cutoff points. Further studies are required to validate and refine the criteria.

Indexed as

diagnostic criteriahematopoietic stem cell transplantationsinusoidal obstruction syndrome

Identifiers

PMID37601886
PMCPMC10435725
OpenAlexW4379052992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.